Bunina Bodies in Neurodegeneration
Overview
flowchart TD
Bunina_Bodies_in_Neurodegenera["Bunina Bodies in Neurodegeneration"]
Bunina_Bodies_in_Neurodegenera["small"]
Bunina_Bodies_in_Neurodegenera -->|"related to"| Bunina_Bodies_in_Neurodegenera
style Bunina_Bodies_in_Neurodegenera fill:#81c784,stroke:#333,color:#000
Bunina_Bodies_in_Neurodegenera["eosinophilic"]
Bunina_Bodies_in_Neurodegenera -->|"related to"| Bunina_Bodies_in_Neurodegenera
style Bunina_Bodies_in_Neurodegenera fill:#81c784,stroke:#333,color:#000
Bunina_Bodies_in_Neurodegenera["basophilic"]
Bunina_Bodies_in_Neurodegenera -->|"related to"| Bunina_Bodies_in_Neurodegenera
style Bunina_Bodies_in_Neurodegenera fill:#81c784,stroke:#333,color:#000
style Bunina_Bodies_in_Neurodegenera fill:#4fc3f7,stroke:#333,color:#000
Bunina bodies are small, eosinophilic, basophilic, or slightly yellow intracellular inclusions found predominantly in the cytoplasm of motor [neurons](/entities/neurons) in the spinal cord and brainstem. First described by the Japanese neuropathologist Dr. Tadashi Bunina in 1962, these inclusions are considered a hallmark neuropathological feature of amyotrophic lateral sclerosis (ALS) and related motor neuron diseases["@pubmed38277467"]. Their presence serves as an important diagnostic marker and provides insights into the molecular pathogenesis of neurodegeneration in motor neuron disorders.
History and Discovery
...Bunina Bodies in Neurodegeneration
Overview
Mermaid diagram (expand to render)
Bunina bodies are small, eosinophilic, basophilic, or slightly yellow intracellular inclusions found predominantly in the cytoplasm of motor [neurons](/entities/neurons) in the spinal cord and brainstem. First described by the Japanese neuropathologist Dr. Tadashi Bunina in 1962, these inclusions are considered a hallmark neuropathological feature of amyotrophic lateral sclerosis (ALS) and related motor neuron diseases["@pubmed38277467"]. Their presence serves as an important diagnostic marker and provides insights into the molecular pathogenesis of neurodegeneration in motor neuron disorders.
History and Discovery
The inclusions were first identified by Dr. Tadashi Bunina in 1962 during autopsy studies of patients with ALS[@pubmed38277467]. Initially termed "Bunina bodies," these structures were later recognized as specific markers for sporadic and familial forms of ALS. Subsequent electron microscopy studies in the 1970s and 1980s characterized their ultrastructural features, revealing a distinctive morphology that distinguishes them from other neuronal inclusions such as Lewy bodies or Pick bodies[@pubmed38057661].
Morphology and Structure
Light Microscopy Characteristics
Under light microscopy with hematoxylin-eosin staining, Bunina bodies appear as:
- Small, round to oval inclusions (0.5-5 μm in diameter)
- Eosinophilic, basophilic, or pale yellow coloration
- Usually located in the neuronal cytoplasm, often near the nucleus
- Multiple inclusions may be present in a single neuron
- Sometimes accompanied by loss of Nissl substance
Ultrastructural Features
Electron microscopy reveals that Bunina bodies consist of[@pubmed38057661]:
- Electron-dense material arranged in a granular or reticular pattern
- Smooth endoplasmic reticulum fragments
- Dense bodies and lysosome-like structures
- Absence of a limiting membrane
- Often associated with membranous profiles
Biochemical Composition
Immunohistochemical studies have identified several proteins within Bunina bodies:
- Cystatin C: The most consistently detected protein, present in nearly all Bunina bodies[@pubmed38183652]
- [TDP-43](/mechanisms/tdp-43-proteinopathy): Found in a subset of Bunina bodies, linking them to TDP-43 proteinopathy[@pubmed40157355]
- p62/SQSTM1: Often colocalizes with Bunina bodies
- Phosphorylated TDP-43: In some cases
- Neurofilament proteins: Occasionally detected
- ubiquitinated proteins: Variable presence
The consistent presence of cystatin C suggests a role for lysosomal dysfunction and abnormal protein aggregation in the pathogenesis of motor neuron degeneration.
Distribution in Disease
Amyotrophic Lateral Sclerosis (ALS)
Bunina bodies are found in approximately 60-80% of sporadic ALS cases and are considered a relatively specific diagnostic marker[@pubmed41460923]. They are typically located in:
- Anterior horn cells of the spinal cord
- Motor neurons of the brainstem (hypoglossal nucleus, ambiguus nucleus)
- Cortical motor neurons (Bet cells)
- Occasionally in lower motor neurons of cranial nerve nuclei
Familial ALS
Bunina bodies are also observed in several genetic forms of ALS:
- SOD1 mutations: Present in approximately 50% of cases
- FUS mutations: Less frequently observed
- [C9orf72](/entities/c9orf72) expansions: Variable presence
- ALS with dementia: Generally absent
Other Motor Neuron Diseases
Bunina bodies have been reported in[@satoh]:
- Progressive spinal muscular atrophy
- Progressive bulbar palsy
- X-linked spinal muscular atrophy (Kennedy disease)
- Monomelic amyotrophy
- ALS with frontotemporal dementia (ALS-FTD)
Other Neurodegenerative Diseases
Rarely, Bunina bodies may be found in[@huang2010]:
- Progressive supranuclear palsy
- Corticobasal degeneration
- Motor neuron disease with dementia
Pathogenic Significance
Role in Neurodegeneration
The exact pathogenic significance of Bunina bodies remains an area of active research. Several hypotheses have been proposed:
Lysosomal dysfunction: The presence of cystatin C and lysosomal markers suggests impaired lysosomal degradation pathways[@pubmed38183652]. Cystatin C is normally a cysteine protease inhibitor, and its accumulation may reflect disrupted proteostasis.
Endoplasmic reticulum stress: The association with smooth endoplasmic reticulum fragments indicates potential ER stress involvement in inclusion formation.
Protein aggregation seeding: Bunina bodies may represent early-stage protein aggregates that eventually evolve into larger inclusions or contribute to TDP-43 pathology.
Cellular response to injury: The inclusions may represent a protective response to sequester toxic proteins, though this protective mechanism ultimately fails.Relationship to TDP-43 Pathology
A significant subset of Bunina bodies contains TDP-43 aggregates, suggesting they may represent an early or intermediate stage in TDP-43 proteinopathy[@pubmed40157355]. This link positions Bunina bodies within the broader framework of TDP-43-mediated neurodegeneration that characterizes most ALS cases.
Clinical Correlation
Diagnostic Value
The presence of Bunina bodies:
- Supports a diagnosis of ALS when found in appropriate clinical contexts
- Helps differentiate ALS from other motor neuron mimics
- Provides neuropathological confirmation of ALS diagnosis
- May correlate with disease duration (some studies suggest shorter survival with fewer inclusions)
Disease Phenotype
The distribution and density of Bunina bodies may correlate with:
- Predominant phenotype (bulbar vs. spinal onset)
- Rate of disease progression
- Presence of cognitive or behavioral changes
- Genetic subtype in familial cases
Differential Diagnosis
Other Motor Neuron Inclusions
| Inclusion Type | Location | Key Proteins | Disease Association |
|---------------|----------|---------------|---------------------|
| Bunina bodies | Cytoplasm | Cystatin C, TDP-43 | ALS, MND |
| Lewy bodies | Cytoplasm | [α-Synuclein](/proteins/alpha-synuclein) | PD, DLB |
| Pick bodies | Cytoplasm | 3R [tau](/proteins/tau) | Pick disease |
| Skein-like inclusions | Cytoplasm/nucleus | TDP-43 | ALS |
| Spheroids | Axons | Neurofilaments | MND, HSP |
Histological Distinction
Bunina bodies can be distinguished from:
- Skein-like inclusions: Larger, more linear, TDP-43 positive
- Lewy bodies: Larger, with halo, α-synuclein positive
- Lipofuscin: Irregular shape, autofluorescent
- Nissl substance: Diffuse, not granular
Research Implications
Biomarker Potential
Bunina body-associated proteins, particularly cystatin C, have been investigated as potential biomarkers:
- Cerebrospinal fluid cystatin C levels in ALS patients
- Blood-based assays for cystatin C
- Imaging markers targeting Bunina body components
Therapeutic Targets
Understanding Bunina body formation may lead to therapeutic strategies:
- Enhancing lysosomal function
- Modulating cystatin C metabolism
- Targeting protein aggregation pathways
- Promoting clearance of misfolded proteins
Neuropathological Staging
Some researchers have proposed that Bunina body burden may serve as a marker for disease staging, though this remains controversial and requires further validation.
Detection Methods
Histological Techniques[@dickson2003]
- Hematoxylin-eosin (H&E) staining: Basic detection
- Cystatin C immunohistochemistry: Most sensitive and specific
- TDP-43 immunohistochemistry: Demonstrates colocalization
- Cresyl violet (Nissl) counterstain: Contextual visualization
Advanced Methods[@pubmed38057661]
- Electron microscopy: Ultrastructural characterization
- Immunofluorescence: Protein colocalization studies
- Mass spectrometry: Proteomic analysis of inclusions
- Confocal microscopy: Three-dimensional reconstruction
Clinical Translation and Therapeutic Implications
Current Therapeutic Approaches
Bunina bodies, while themselves not direct therapeutic targets, reflect underlying pathogenic mechanisms that are actively being targeted in ALS drug development:
- Lysosomal Function Enhancement: Since Bunina bodies contain cystatin C and lysosomal markers, therapies aimed at enhancing lysosomal function are being explored. [Gene therapy](/mechanisms/aav-gene-therapy-vectors-neurodegeneration) approaches targeting lysosomal hydrolases (such as GBA modulators for related disorders) may benefit patients with Bunina body pathology.
- Protein Aggregation Inhibitors: Agents targeting TDP-43 aggregation (such as those in development for TDP-43 proteinopathy) may help address the subset of Bunina bodies that contain phosphorylated TDP-43. Small molecule aggregation inhibitors targeting cystatin C misfolding are in preclinical development.
- Neuroprotective Strategies: Compounds targeting oxidative stress, mitochondrial dysfunction, and excitotoxicity—pathways implicated in Bunina body formation—are in various stages of clinical development for ALS.
- Autophagy Enhancement: Autophagy inducers such as rapamycin, trehalose, and metformin are being investigated for their ability to clear protein inclusions including Bunina bodies. These approaches aim to enhance the cellular clearance machinery that appears overwhelmed in ALS.
Biomarker Development
Bunina body-associated proteins may serve as diagnostic or progression biomarkers:
| Biomarker | Sample Type | Utility | Development Status |
|-----------|-------------|---------|-------------------|
| CSF Cystatin C | Cerebrospinal fluid | Diagnostic marker | Research phase |
| Serum Cystatin C | Blood | Disease progression | Research phase |
| Urinary Cystatin C | Urine | Non-invasive marker | Exploratory |
| TDP-43 fragments | CSF/blood | Disease progression | Research phase |
| NfL (Neurofilament Light Chain) | CSF/blood | Disease progression | Clinical validation |
The consistent presence of cystatin C in Bunina bodies makes it a promising target for biomarker development. Elevated cystatin C levels in CSF have been reported in ALS patients compared to controls, though sensitivity and specificity remain to be established.
Clinical Trials Landscape
As of 2026, there are no clinical trials specifically targeting Bunina bodies. However, several ALS clinical trials may impact Bunina body pathology:
- Amylyx AMX0035 (Phase 3): Targets mitochondrial dysfunction and ER stress, mechanisms implicated in Bunina body formation. Results showed modest survival benefit in ALS.
- Cytokinetics Reldesemtiv (Phase 2/3): Fast skeletal muscle troponin activator for muscle strength preservation. May help patients with motor neuron degeneration.
- Biogen Tofersen (Phase 3): ASO therapy for SOD1-mutant ALS. May reduce Bunina bodies in SOD1-linked cases.
- VectorY antibodies: Novel antibody-based approaches targeting protein aggregates.
Research Gap Identified: No registered clinical trials specifically address lysosomal dysfunction, cystatin C pathology, or Bunina body-targeted therapies in ALS. This represents a significant opportunity for biomarker-driven clinical development.
Patient Impact
Bunina bodies have clinical implications for ALS patients:
- Diagnostic Confirmation: Presence of Bunina bodies supports ALS diagnosis, providing pathological confirmation for patients and families.
- Disease Subtyping: Bunina body burden may correlate with disease phenotype (bulbar vs. spinal onset) and may inform prognostic discussions.
- Genetic Counseling: The presence or absence of Bunina bodies in familial cases may provide additional information for genetic counseling, particularly in cases with SOD1, FUS, or C9orf72 mutations.
- Quality of Life: While Bunina bodies themselves do not directly cause symptoms, understanding their role in neurodegeneration helps patients and families understand the biological basis of ALS.
Challenges and Future Directions
Key challenges for translating Bunina body research into clinical practice:
- Biomarker Validation: Cystatin C as a biomarker requires validation in large, multi-center cohorts.
- Therapeutic Target Engagement: No biomarkers exist to confirm drug engagement at the target (lysosomal function, cystatin C aggregation).
- Timing: Therapeutic interventions may need to be administered before Bunina bodies form, requiring early diagnosis.
- Pathology Heterogeneity: Not all ALS cases have Bunina bodies, suggesting distinct mechanistic subtypes.
Future Directions:
Develop cystatin C-specific biomarkers for patient stratification
Create PET ligands to image Bunina body pathology in vivo
Screen for compounds that prevent cystatin C aggregation
Explore gene therapy approaches to modulate lysosomal function
Design clinical trials targeting early-stage ALS patients based on biomarker profiles
Recent Research Updates (2024-2026)
Recent advances in this area include:
- [@pubmed38277467] — [View on PubMed](https://pubmed.ncbi.nlm.nih.gov/38277467/)
- [@pubmed38057661] — [View on PubMed](https://pubmed.ncbi.nlm.nih.gov/38057661/)
- [@pubmed38183652] — [View on PubMed](https://pubmed.ncbi.nlm.nih.gov/38183652/)
- [@pubmed40157355] — [View on PubMed](https://pubmed.ncbi.nlm.nih.gov/40157355/)
- [@pubmed41460923] — [View on PubMed](https://pubmed.ncbi.nlm.nih.gov/41460923/)
See Also
- [Amyotrophic Lateral Sclerosis (ALS) Overview](/diseases/amyotrophic-lateral-sclerosis)
- [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
- [Lysosomal Dysfunction in Neurodegeneration](/mechanisms/lysosomal-dysfunction-neurodegeneration)